Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (251-260 of 315) with videos related to

Pageof 32
Sort By:
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Urologic Oncology|May 4, 2020
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trialNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Future Oncology (London, England)|June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genesKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate CancerJames L Gulley, Michael Borre, Nicholas J Vogelzang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Journal of Sexual Medicine|May 25, 2016
Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study"Kevin T McVary, Steven N Gange, Marc C Gittelman, et al.
The Journal of Sexual Medicine|May 1, 2016
Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled StudyKevin T McVary, Steven N Gange, Marc C Gittelman, et al.
The Journal of Urology|November 29, 2015
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaKevin T McVary, Steven N Gange, Marc C Gittelman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyArun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Pageof 32

Showing results (251-260 of 315) with videos related to

Sort By:
Pageof 32
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Urologic Oncology|May 4, 2020
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trialNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Future Oncology (London, England)|June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genesKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate CancerJames L Gulley, Michael Borre, Nicholas J Vogelzang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Journal of Sexual Medicine|May 25, 2016
Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study"Kevin T McVary, Steven N Gange, Marc C Gittelman, et al.
The Journal of Sexual Medicine|May 1, 2016
Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled StudyKevin T McVary, Steven N Gange, Marc C Gittelman, et al.
The Journal of Urology|November 29, 2015
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaKevin T McVary, Steven N Gange, Marc C Gittelman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 studyArun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Pageof 32